RecruitMe Clinical Trial

AINV18P1: A Phase 1 Study of Palbociclib, a CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Palbociclib and Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Sponsor:Children's Oncology Group
Enrolling:Male and Female Patients
Age Range:Between 1 and 31 years old
IRB Number:AAAS2612
U.S. Government ID:NCT03792256
Contact: Rebecca Zylber, NP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United States (US) Food and Drug Administration (FDA) for treating children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib is given by mouth once daily for the first 21 days of the 32-day cycle. It will be given in combination with standard chemotherapy.

Do You Qualify?
Do you have ALL or LL that has come back after treatment or is not responding to treatment?YesNo
Are you between 1 and 31 years of age?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rebecca Zylber, NP
Email: rjv2107@cumc.columbia.edu
Phone: 212-305-7212